Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China Zai Lab and Cullinan Oncology Announce Strategic Collaboration and License Agreement for CLN-081 in Greater China Matt Burke2020-12-28T08:16:19-05:00December 28, 2020| Read More
Cullinan Oncology Completes $131.2 Million Series C Financing Cullinan Oncology Completes $131.2 Million Series C Financing Matt Burke2020-12-17T07:59:32-05:00December 17, 2020| Read More
Jon Wigginton MD Receives SITC Visionary Legacy Award Jon Wigginton MD Receives SITC Visionary Legacy Award Matt Burke2020-11-13T12:19:46-05:00November 13, 2020| Read More
Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer Cullinan Oncology Appoints Jeff Trigilio as Chief Financial Officer root2020-11-13T10:09:14-05:00October 29, 2020| Read More
Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020 Cullinan Pearl Announces Presentation of Preliminary Safety and Efficacy of CLN-081 in EGFR Exon 20 NSCLC Patients at ESMO Virtual Congress 2020 Matt Burke2020-09-17T08:47:26-05:00September 17, 2020| Read More
Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML Cullinan Oncology, German Cancer Research Center (DKFZ) and the University of Tübingen Announce the Formation of Cullinan Florentine to Develop CLN-049, a Novel Bispecific Antibody for AML root2020-09-15T07:30:14-05:00September 15, 2020| Read More
Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy Cullinan Oncology Launches Cullinan Amber to Pioneer Next-Generation Cytokine Fusion Proteins for Cancer Therapy root2020-07-22T17:52:30-05:00July 22, 2020| Read More
Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing Cullinan Oncology and PDI Therapeutics Join Forces to Bring Novel, First-In-Class Immuno-Oncology Antibody into the Clinic through a $26M Series A Financing root2020-06-11T11:36:55-05:00June 11, 2020| Read More
Cullinan Oncology Completes $98.5 Million Series B Financing Cullinan Oncology Completes $98.5 Million Series B Financing root2020-06-03T16:12:17-05:00June 3, 2020| Read More
